

IMPACT OF INHALERS ON CO₂ EMISSION IN A HEALTH AREA

A. Luaces-Rodríguez¹, P. Feijoo-Vilanova¹, L. Caeiro-Martínez¹, E. Gómez-Costa¹,
A. Martínez-Pradedá¹, S. Rotea-Salvo¹, S. Albiñana-Pérez¹, I. Martín-Herranz¹.

¹Pharmacy Department, A Coruña University Hospital Complex, A Coruña (Spain)


SPD-018
R03- DRUGS FOR OBSTRUCTIVE
AIRWAY DISEASES



andrea.luaces.rodriguez@sergas.es

BACKGROUND AND IMPORTANCE

There are several types of devices for inhaled therapy, being the most used ones: **pressurised metered-dose inhalers (pMDIs)**, dry-powder inhalers (DPIs) and **soft mist inhalers (SMIs)**. All the types have some environmental impact due to their effect on **CO₂ emissions**, although very low compared to total CO₂ emissions, pMDIs have proven to exert higher CO₂ emissions than DPIs and SMIs.



AIM AND OBJECTIVES

The main objective is to estimate the **impact of inhalers** (pMDIs, DPIs and SMIs), prescribed for any indication, on CO₂ emissions in our health care area during one year.




MATERIAL AND METHODS

Number of inhalers consumed in our health care area with a population of 550086 inhabitants during 2022 was extracted from the General Subdirectorate of Pharmaceuticals. The inhalers' **carbon footprint** values were extracted from the publication Montoro et al.

Carbon footprint estimated mean value (Kg CO ₂ -eq/year/pack)	
pMDIs	16.69
DPIs	1.02
SMIs	0.59

RESULTS



	Inhalers consumed		Carbon footprint		
	N	%	Kg CO ₂ -eq/year/pack	Kg CO ₂ -eq/year	%
pMDIs	137678	39.21 %	16.69	2297845.82	91.69 %
DPIs	191278	54.47 %	1.02	195103.56	7.79 %
SMIs	22212	6.33 %	0.59	13105.08	0.52 %
Total	351168			2506054.46	

CONCLUSION AND RELEVANCE

The carbon footprint of the pMDIs represented more than 90 % of the total carbon footprint of all the inhalers, even when consumption of pMDIs represented less than the 40 %. This put in evidence the considerable **higher environmental impact of pMDIs compared to DPIs**.

However, this does not go in line with several societies and organisms which keep defending that efficacy, safety and patient suitability must continue to be the main factors when choosing a type of inhaler for each patient.

REFERENCES AND ACKNOWLEDGEMENTS

Montoro J, et al. Impact of Asthma Inhalers on Global Climate: A Systematic Review of Their Carbon Footprint and Clinical Outcomes in Spain. J Investig Allergol Clin Immunol. 2023 Jul 27;33(4):250-262. doi: 10.18176/jiaci.0887.

The authors acknowledged the General Subdirectorate of Pharmaceuticals – Galician Health Service (Spain).